Changes in Brachial and Central Blood Pressure after Short Term Continuous Positive Airway Pressure Treatment of Patients with Moderate-to-Severe Obstructive Sleep Apnoea and Impaired Renal Function

Bodil G. Hornstrup1*, Pia H. Gjørup2, Jost Wessels2, Thomas G. Lauridsen1,2, Erling B. Pedersen1, Jesper N. Bech1,2

1University Clinic in Nephrology and Hypertension, Regional Hospital West Jutland and Aarhus University, Aarhus, Denmark
2Department of Medicine, Regional Hospital West Jutland, Holstebro, Denmark

Email: *bodil.hornstrup@rm.dk

Abstract

**Background:** Previous studies of continuous positive airway pressure (CPAP) treatment for obstructive sleep apnoea (OSA) have shown conflicting results on the effect on blood pressure (BP), and patients with chronic kidney disease (CKD) have not been included in these studies. As OSA is a frequent comorbidity in patients with CKD, it is of relevance to evaluate the effect of CPAP treatment on BP in this population. **Aim:** In this prospective follow-up study, we measured the effect of short term CPAP treatment of moderate-to-severe OSA on brachial and central BP, plasma level of syndecan-1 and vasoactive hormones, renal handling of sodium, subjective sleepiness, and quality of life in patients with impaired renal function. **Methods:** From December 2015 until March 2017, 25 patients were invited to participate in the study at the University Clinic in Nephrology and Hypertension, Aarhus University and Holstebro Hospital. At baseline and at follow-up after three to four months of CPAP treatment, we performed 24 h brachial and central ambulatory BP measurement, blood sampling measurements of plasma concentrations of syndecan-1, renin, angiotensin II, aldosterone, vasopressin, creatinine, haemoglobin A1c, and cholesterol, cardio respiratory monitoring, 24 h urine collection for measurement of urinary excretion of albumin, aquaporin-2, and epithelial sodium channel, Epworth Sleepiness Scale (ESS), and SF-36 (quality of life). **Results:** At follow-up, the 17 included patients with mean baseline estimated glomerular filtration rate 66 mL/min/1.73 m² had a sig-
significant decrease in systolic office-, 24 h- and daytime-BP (13, 7, and 8 mmHg, respectively, \( p < 0.05 \)), a non-significant reduction of nocturnal BP (6 mmHg). No changes was measured in frequency of non-dipping or in central 24 h-, day- and nighttime-BP. Renal function remained unchanged, but urinary albumin excretion fell. ESS was unchanged. Quality of life improved. Conclusion: Short-term CPAP treatment of patients with moderate-to-severe OSA and reduced renal function decreased 24 h- and daytime-BP significantly and reduced urinary albumin excretion. Our results underline the importance of treatment of OSA in hypertensive patients with impaired renal function.

Keywords
Chronic Kidney Disease, Nocturnal Blood Pressure, Obstructive Sleep Apnoea, Central Blood Pressure, Continuous Positive Airway Pressure

1. Introduction
Obstructive sleep apnoea (OSA) is a frequent comorbidity in hypertension and chronic kidney disease (CKD) [1] [2]. OSA is characterised by obstructions of the upper airways during nighttime sleep causing repetitive pauses in breathings despite respiratory efforts. Termination of the obstructions requires arousal, which leads to poor sleep quality and daytime sleepiness in OSA patients. OSA patients show early signs of atherosclerosis and are of increased risk of stroke independent of other known risk factors such as hypertension, diabetes, smoking, and body mass index (BMI) [3] [4]. Furthermore, the nocturnal hypoxemia seen in OSA is associated to progression of renal failure [5] [6].

Continuous positive airway pressure (CPAP) has been an established treatment for OSA for many years with a documented improving effect on sleep, quality of life, and nocturnal hypoxemia [7] [8] [9]. High CPAP compliance is associated with lower risk of cardiovascular disease and with a renoprotective effect independent of blood pressure (BP) reduction [10] [11]. Different effects of CPAP treatment on BP levels have been reported; some studies show significant lowering effect [7], whereas other studies demonstrate sparse effect [12] [13] [14]. No studies have analysed the effect of CPAP treatment in patients with CKD; hence, short term effects (three to four months) of CPAP treatment of moderate-to-severe OSA in patients with CKD are unknown with respect to brachial BP, quality of life, and sleep symptoms.

Central aortic systolic pressure (CASP) may provide additional information on the level of arteriosclerosis and cardiovascular disease associated end organ damage [15] [16]. CPAP treatment has been shown to lower the central systolic pressure using twice-a-day measurements in normo- and uncomplicated essential hypertensive patient with OSA [17]. However, the effect of CPAP treatment on CASP has not been clarified in CKD patients.

Increased syndecan-1 in plasma is an indication of increased shedding from
the glycocalyx protection layer as a response to cardiovascular stress [18]. We have previously found increased syndecan-1 levels in hypertensive patients compared with healthy controls [19]. However, it is not known, whether CPAP treatment can alter plasma levels of syndecan-1, and thereby be an indicator of reduced shedding as a response to CPAP treatment.

The aim of this intervention study was to evaluate the effect of short term CPAP treatment in subjects with moderate-to-severe OSA (apnoea hypopnoea index (AHII) > 15) and impaired renal function (estimated glomerular filtration rate (eGFR) 15 - 89 mL/min/1.73 m² at sampling time) on 1) brachial and central BP, 2) p-syndecan-1, 3) plasma levels of renin, angiotensin II, aldosterone, and vasopressin, 4) eGFR and urinary excretion of albumin, aquaporin-2, and a fraction of the epithelial sodium channel, 5) quality of life, and 6) subjective sleepiness.

2. Materials and Methods

2.1. Design

The project was carried out as a prospective intervention study. Patients were included at the time of start of CPAP treatment and followed up after approximately three to four month.

2.2. Study Settings

The study was conducted at the University Clinic in Nephrology and Hypertension, Aarhus University and Holstebro Hospital, and the Sleep Apnoea Clinic, Department of Medicine, Holstebro Hospital. The recruitment period was from December 2015 until March 2017.

2.3. Patients

Patients were recruited from the Renal Outpatient Clinic, Holstebro Hospital (eGFR 15 - 59 mL/min/1.73 m²) or from a population study in Holstebro County (diagnosis of hypertension and eGFR 60 - 89 mL/min/1.73 m²) [20]. All patients were diagnosed with moderate-to-severe OSA and had not received CPAP treatment previously. The patients were examined for OSA during participation in two other projects by the same authors [19] [21]. They were offered CPAP treatment according to usual clinical practice.

Inclusion criteria: men and women, age 18 - 80, eGFR 15 to 89 mL/min/1.73 m², OSA with apnoea hypopnoea index (AHII) ≥ 15. Exclusion criteria: unwillingness to participate, malignant disease, drug abuse, alcohol abuse (>21/>14 drinks per week for males and females, respectively), atrial fibrillation or heart failure, liver disease (alanine aminotransferase > 200 U/L), severe chronic obstructive lung disease (forced expiratory volume in 1 second (FEV₁) less than 50% of expected), and difference in BP between right and left arm above 10/10 mmHg. Withdrawal criteria: development of exclusion criteria, lack of completion of participation, and lack of compliance.
Number of subjects: the minimal relevant difference in mean 24 h systolic BP (SBP) was 10 mmHg with standard deviation (SD) 10. With a statistical power of 80% and a significance level of 5%, it was calculated that the number of subjects should be at least 16.

2.4. Ethics

This study was reviewed and approved by the Central Denmark Region Committees on Health Research Ethics (j.no.: M-2013-285-13 and M-2013-304-13) and by the Danish Data Protection Agency (j.no.: 1-16-02-399-13 and 1-16-02-458-13). The study was carried out in accordance with the Helsinki Declaration. All study patients received oral and written information about the project and provided informed written consent prior to study enrolment. ClinicalTrials.gov registration identification was NCT01951248 and NCT02078778.

2.5. End Points

The primary end point was change in brachial 24 h SBP after three to four months of CPAP treatment.

The secondary end points were changes in: 24 h central BP, relative nocturnal brachial SBP and CASP decrease, urinary excretion rate of aquaporin-2 (u-AQP2) and epithelial sodium channel fraction γ (u-ENaCγ), 24 h urine excretion of albumin (u-albumin), p-synecan-1, vasoactive hormones (plasma renin concentration, plasma aldosterone, plasma angiotensin II, plasma arginine vasopressin (p-AVP)), reporting of subjective sleepiness (Epworth Sleepiness Scale, ESS), and quality of life (by SF-36 questionnaire).

2.6. Blood Pressure

Twenty-four hour ambulatory BP measurement (ABPM) was carried out using an oscillometric device, A&D TM-2430 (A&D Company Limited, Tokyo, Japan). An appropriate size cuff was chosen after measuring the upper arms circumference and placed on the right side. Twenty-four hour CASP was measured using applanation tonometry by BPro Health Stat (BPro, HealthSTATS, Singapore). The BPro device was placed on the left wrist after being calibrated with a mean of the last three of four consecutive BP measurements on the left arm derived from the A&D device used for 24 h brachial ABPM on the same subject.

BP was measured every 15 min and every 30 min during day- and nighttime, respectively, by the A&D device, and every 15 min by the BPro device throughout the 24 hours. ABPM were considered satisfactory with 14 or more daytime recordings (fixed daytime setting at 6 am to 11 pm) and seven or more nighttime recordings (fixed nighttime setting at 11 pm to 6 am).

A semiautomatic oscillometric device, Omron 705IT (Omron Matsusaka CO, Ltd., Matsusaka City, Japan) was used for bilateral brachial BP measurements with the subject sitting in upright position after minimum ten minutes rest.

Hypertension was defined as brachial 24 h BP ≥ 130 mmHg systolic and/or ≥
80 mmHg diastolic, non-dipping was defined as relative nocturnal systolic BP decrease ≤10%, and resistant hypertension was defined as hypertension on three antihypertensive drugs, one of these being a diuretic. These definitions are according to most recent guidelines from the European Society of Hypertension/European Society of Cardiology [22].

2.7. Sleep Apnoea

An ambulatory cardio respiratory monitoring (CRM) was performed using Embletta Gold (Natus Medical Incorporated, USA) in all participants at baseline and follow-up. RemLogic-E Software was used for analysing and storing data. The sleep report was generated from sleep time and consisted of continuous recordings from the Embletta monitor. During sleep, this monitor recorded airflow from a nasal pressure transducer, arterial oxygen saturation from a pulse oximeter, respiratory effort from thoracic and abdominal impedance belts, and body position from sensors. An apnoeic event was defined as a cessation of nasal airflow accompanied by a drop of the signal below 10% of the reference amplitude for an interval of 10 seconds. A hypopnoeic event was defined as a reduction of the signal below 70% of the reference amplitude for an interval of 10 seconds with a subsequent desaturation event no later than 20 seconds after the start of the event. An oxygen desaturation event was observed by a decrease in oxygen saturation by at least 4%. Events lasting longer than 120 seconds (apnoea, hypopnea, or desaturation) were excluded.

Apnoea hypopnoea index (AHI) was defined as the sum of apnoeas and hypopnoeas per hour of registered sleep. Oxygen desaturation index (ODI) was defined as oxygen desaturation events pr. hour of sleep. OSA was defined as AHI ≥ 5, moderate-to-severe OSA ≥ 15. Definitions above are according to recommendations from the American Academy of Sleep Medicine (AASM) [23].

2.8. Continuous Positive Airway Pressure (CPAP)

OSA was treated with AirSense 10 AutoSet (ResMed/Maribo Medico) or REMstar Auto with A-Flex (Phillips/Respironics). Treatment was started and followed up by trained nurses in the Sleep Apnoea Clinic, Department of Medicine, Holstebro Hospital, according to standard procedure. A mask for the CPAP treatment was chosen to the best fit for the patient, either nasal or full face mask. The two systems had identical functionality and were self-adjusting; the pressure was automatically adjusted in response to inhalation flow, snoring, and apnoeas. The subjects were instructed in correct use of the system, change of air filter, and daily maintenance/cleaning of the system. Humidifier was added to the system if needed. Adherence was defined from the last month of treatment as percentage of 4 hours every night; the patient had been using the equipment.

2.9. Experimental Procedures

Subjects received oral and written information about this project after being diagnosed with moderate-to-severe OSA (AHI ≥ 15) in previous studies. An in-
formation meeting was set up, and after informed written consent, lifestyle questionnaire (SF-36) was filled in by the patient alone after instructions were given, and follow-up meeting was planned. Baseline information on ABPM, CRM, blood and urine samples, medical treatment, sleep symptoms (Epworth Sleepiness Scale (ESS)), and medical history were collected from the previous project participation.

While participating in this study, patients followed their usual consultations in the Renal Outpatient Clinic or general practitioners with regard to their renal disease or hypertensive disease. At these consultations, antihypertensive medications were adjusted if necessary. This was assessed by the patient’s physician in the Outpatient Clinic or the general practitioner.

At baseline and at follow-up after approximately three to four months of CPAP treatment, subjects were examined as described in the following section. Blood samples were drawn after 20 min of rest in supine position. Twenty-four hour brachial and central ABPM were carried out simultaneously, and 24 h urine collection was performed and returned at the latest 4 hour after completion. CRM, as described above, was completed, and at follow-up the CRM was carried out simultaneously with CPAP treatment, and adherence was registered from the CPAP device. Information on changes in use of medication and eventual new medical events were obtained by the electronic patient record and questionnaire, respectively. Current quality of life and subjective sleepiness were reported by SF-36 and ESS, respectively. These questionnaires were filled in by the participant alone after a short introduction.

2.10. Biochemical Analyses

Blood samples were centrifuged at 4°C for 10 min at 2200 × g. Plasma samples were kept frozen at −20°C (P-Angiotensin II) and −80°C (Syndecan, plasma renin concentration, P-aldosterone, and p-AVP), and urine samples at −20°C until assayed.

Urinary and plasma osmolality were measured by freezing-point depression (Advanced Model 3900 multisampling osmometer).

Plasma renin concentration was determined by radioimmunoassay using a kit from CIS Bio International, Gif-Sur-Yvette Cedex, France. Minimal detection level was 1 pg/mL. The coefficients of variations were 14.5% (inter-assay) and 4.5% (intra-assay).

P-Angiotensin II and p-AVP were extracted from plasma with C18 Sep-Pak (Water associates, Milford, MA, USA), and subsequently determined by radioimmunoassay [24] [25]. The antibody against Ang II was obtained from the Department of Clinical Physiology, Glostrup Hospital, Denmark. Minimal detection level was 2 pmol/L. The coefficients of variation were 12% (inter-assay) and 8% (intra-assay). The antibody against AVP was a gift from Professor Jacques Dürr, Miami, FL., USA. The coefficients of variation were 13% (inter-assay) and 9% (intra-assay). Minimal detection level was 0.5 pmol/L.

P-aldosterone was determined by radioimmunoassay using a kit from
Demeditec Diagnostics GmbH, Kiel, Germany. The coefficients of variations were 17.2% (inter-assay) and 12.6% (intra-assay). Minimal detection level was 3.99 pmol/L.

P-syecan-1 was analysed on EDTA-plasma using a human ELISA kit from Abcam plc, Cambridge, United Kingdom. The coefficients of variations were 10.2% (inter-assay) and 6.2% (intra-assay). Minimal detection level was 4.94 ng/mL.

U-AQP2 was determined by RIA as previously described [26] [27]. Rabbit anti-AQP2 antibodies were a gift from Professor Soren Nielsen and Professor Robert Fenton, the Water and Salt Research Center, Aarhus University, Denmark. Coefficients of variation: 11.7% (inter-assay) and 5.9% (intra-assay). Minimal detection level: 32 pg/tube.

U-ENaCγ was measured by RIA as described previously [28] [29]. ENaCγ was synthesized and purchased by Lofstrand, Gaithersburg, Maryland, USA. The ENaCγ antibody was a gift from Professor Soren Nielsen and Professor Robert Fenton, the Water and Salt Center, Aarhus University. Coefficients of variation: 10% at a mean level of 338 pg/tube (inter-assay), 9% at a mean level of 743 pg/tube (inter-assay), 5.0% in the range 125 - 135 pg/tube (intra-assay), and 5.6% in the range 290 - 380 pg/tube (intra-assay). Minimal detection level: 35 pg/tube.

Plasma levels of creatinine, hemoglobin A1c (Hba1c), cholesterol, and urinary concentrations of albumin, creatinine, and sodium were measured using routine methods at the Department of Clinical Biochemistry, Holstebro Hospital, Denmark. eGFR was calculated by the MDRD-equation.

2.11. Statistical Methods

Statistical analyses were performed by the authors using IBM SPSS statistics version 22 (IBM Corp.; Armonk, NY, United States). All data were tested for normality and variance equality. The statistical level of significance was p < 0.05 in all analyses.

Continuous variables were reported as means with SD or as median with interquartile rang [25; 75] depending on whether the data were normally distributed or not. Categorical variables were reported as percentages with number. Paired t-tests were used for paired continuous variables with normally distributed differences; otherwise Wilcoxon signed rank test was used. McNemar's test was used for paired categorical data. Univariate analyses were performed using Pearson’s test or Spearman Rho test on normally distributed or non-normally distributed continuous variables, respectively.

The SF36 questionnaire filled out by the patients was scored using the procedure from International Resource Center for Health Care Assessment (Boston, MA), called RAND 36-Item Health Survey 1.0 [30].

3. Results

3.1. Demographics

Twenty-five patients were invited to participate; two were not included as they never began CPAP treatment despite initial intention to do so. Six were ex-
cluded; four due to early discontinuation of treatment (within one month), and two due to uncompleted follow-up examination (incomplete data). Seventeen participants completed follow-up examination (Figure 1).

Baseline clinical, laboratory, and sleep characteristics of the included 17 patients are presented in Table 1. Mean eGFR were 66 mL/min/1.73 m², and 36% (n = 6) were diagnosed with diabetes. All participants were diagnosed with hypertension, and 76% (n = 13) received antihypertensive medication. Of them, 23% (n = 3) were controlled hypertensive, and 54% (n = 7) had resistant hypertension.

At baseline and follow-up, subjects received a mean of 3.7 ± 4.4 and 3.8 ± 4.5 defined daily doses (DDD) of BP lowering drugs, respectively (p > 0.05). Twelve subjects’ DDD remained unchanged, one subject’s DDD decreased (0.25 DDD), and four subjects’ DDD increased (mean change 0.8 DDD). Forty-two percent (n = 7) received statins throughout the follow-up period.

3.2. Brachial Blood Pressure

Table 2 shows baseline and follow-up brachial BP; brachial systolic and diastolic office, 24 h and daytime BP decreased significant at follow-up. No changes were observed in nocturnal BP or nocturnal BP decrease. The frequency of non-dipping was unchanged (at baseline 47% (n = 8) and follow-up 53% (n = 9), p = 1.0 (Figure 2(a)).

3.3. Central Arterial Systolic Pressure

Two patients’ baseline and one patient’s follow-up CASP measurement was excluded from analysis due to few measurements. Therefore, CASP analyses included 14 patients’ measurements. There was a non-significant decrease in 24 h, day and nighttime CASP (Table 2). Non-dipping was seen in 64% (n = 9) at baseline, and 86% (n = 12) at follow-up (p = 0.45) (Figure 2(b)).

Figure 1. Flow chart of patients.
Figure 2. Percentage of patients with dipping/non-dipping blood pressure pattern at baseline and follow-up in brachial (a) and CASP (b) values. Percentage (number) of subjects with nocturnal systolic blood pressure decrease ≤ 10% of day time blood pressure as non-dippers/dippers, respectively. Abbreviations. CASP: central aortic systolic pressure. Brachial: $p = 1.0$, CASP: $p = 0.45$. Statistics were performed using McNemars test.

Table 1. Demographics and sleep characteristics at baseline.

<table>
<thead>
<tr>
<th>Demographic Characteristics</th>
<th>N = 17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>65 (7)</td>
</tr>
<tr>
<td>Gender, male, % (n)</td>
<td>77 (13)</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>34 (7)</td>
</tr>
<tr>
<td>Estimated glomerular filtration rate, ml/min/1.73 m²</td>
<td>66 (23)</td>
</tr>
<tr>
<td>U-albumin, mg/24 hour</td>
<td>11 [7; 138]</td>
</tr>
<tr>
<td>Haemoglobin A1c, mmol/mol</td>
<td>49 (15)</td>
</tr>
<tr>
<td>Total cholesterol, mmol/L</td>
<td>4.9 (1.0)</td>
</tr>
<tr>
<td>High density lipoprotein cholesterol, mmol/L</td>
<td>1.1 (0.3)</td>
</tr>
<tr>
<td>Triglyceride, mmol/L</td>
<td>2.2 (1.1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sleep Characteristics</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Epworth Sleepiness Scale (ESS), 0 - 24</td>
<td>5.0 [3.5; 8.5]</td>
</tr>
<tr>
<td>Apnoea hypopnoea index (AHI), events pr. hour</td>
<td>33 [20; 37]</td>
</tr>
<tr>
<td>Oxygen desaturation index (ODI), events/hour</td>
<td>36 [17; 51]</td>
</tr>
<tr>
<td>Mean oxygen saturation, %</td>
<td>92 (2)</td>
</tr>
</tbody>
</table>

Baseline demographic characteristics and baseline sleep data from all 17 patients. Data are presented as mean (SD) except u-albumin, Epworth Sleepiness Scale, Apnoea hypopnoea index, and oxygen desaturation index, which are presented as median with interquartile range [25%; 75%]. *From Epworth Sleepiness Scale, self-reported data.

The changes in brachial and central BP from baseline to follow-up were similar (data not shown).

3.4. Sleep Examination

Follow-up time was median 89 days with a total range from 72 to 139 days. Data from sleep examination at baseline are showed in Table 1. At follow-up, AHI and ODI decreased and mean oxygen saturation ($\text{SaO}_2$) increased, while sleep symptoms (ESS) were reported unchanged (Table 3). Adherence to CPAP
Table 2. Brachial blood pressure and central aortic systolic pressure at baseline and at follow-up.

<table>
<thead>
<tr>
<th></th>
<th>Brachial (n = 17)</th>
<th>CASP (n = 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Follow-up</td>
</tr>
<tr>
<td>Office BP systolic, mmHg</td>
<td>149 (13)</td>
<td>136 (15)*</td>
</tr>
<tr>
<td>Office BP diastolic, mmHg</td>
<td>87 (7)</td>
<td>79 (12)*</td>
</tr>
<tr>
<td>24 hour BP, systolic, mmHg</td>
<td>143 (11)</td>
<td>136 (8)*</td>
</tr>
<tr>
<td>24 hour BP, diastolic, mmHg</td>
<td>81 (7)</td>
<td>78 (7)**</td>
</tr>
<tr>
<td>24 hour heart rate, beats/min</td>
<td>68 (7)</td>
<td>68 (7)</td>
</tr>
<tr>
<td>Daytime BP, systolic, mmHg</td>
<td>146 (11)</td>
<td>138 (9)*</td>
</tr>
<tr>
<td>Daytime BP, diastolic, mmHg</td>
<td>83 (8)</td>
<td>79 (7)*</td>
</tr>
<tr>
<td>Nighttime BP, systolic, mmHg</td>
<td>131 (16)</td>
<td>125 (14)</td>
</tr>
<tr>
<td>Nighttime BP, diastolic, mmHg</td>
<td>74 (6)</td>
<td>72 (7)</td>
</tr>
<tr>
<td>Absolute nocturnal BP decrease, mmHg</td>
<td>15 (12)</td>
<td>13 (14)</td>
</tr>
<tr>
<td>Relative nocturnal BP decrease, %*</td>
<td>10 (8)</td>
<td>9 (10)</td>
</tr>
</tbody>
</table>

Abbreviations: BP: blood pressure. CASP: central aortic systolic pressure. Office blood pressure obtained from baseline and follow-up examinations. 24 h, day and nighttime brachial and CASP data obtained from 24 h ABPM. CASP measurements only consist of systolic values from 24 h central ABPM. Data are presented as mean (SD). *Relative systolic decrease from day time to night time. Statistics were performed using paired t-test. *p < 0.05, **p < 0.001.

Table 3. Changes in body mass index, laboratory results, and sleep parameters at follow-up.

<table>
<thead>
<tr>
<th></th>
<th>n = 17</th>
<th>▲ value</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Metabolic parameters</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>0.2 (4.8)</td>
<td>0.88</td>
<td></td>
</tr>
<tr>
<td>Haemoglobin A1c, mmol/mol</td>
<td>0.7 (4.4)</td>
<td>0.55</td>
<td></td>
</tr>
<tr>
<td>Total cholesterol, mmol/L</td>
<td>−0.3 (1.1)</td>
<td>0.25</td>
<td></td>
</tr>
<tr>
<td>High density lipoprotein cholesterol, mmol/L</td>
<td>−0.0 (0.2)</td>
<td>0.67</td>
<td></td>
</tr>
<tr>
<td>Triglyceride, mmol/L</td>
<td>−0.2 (0.9)</td>
<td>0.31</td>
<td></td>
</tr>
<tr>
<td><strong>Renal parameters</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estimated glomerular filtration rate, mL/min/1.73 m²</td>
<td>0.7 (10.4)</td>
<td>0.77</td>
<td></td>
</tr>
<tr>
<td>U-albumin, mg/24 hour</td>
<td>−3 [−1; 31]</td>
<td>0.025</td>
<td></td>
</tr>
<tr>
<td><strong>Sleep parameters</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epworth Sleepiness Scale (ESS), 0 - 24*</td>
<td>−1 [−3; 1]</td>
<td>0.112</td>
<td></td>
</tr>
<tr>
<td>Apnoea hypopnoea index (AHI), events pr. hour</td>
<td>−27 [−19; −38]</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>Oxygen desaturation index (ODI), events/hour</td>
<td>−33 [−15; −48]</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>Mean oxygen saturation, %</td>
<td>3 (2)</td>
<td>0.001</td>
<td></td>
</tr>
</tbody>
</table>

Values represent follow-up minus baseline values. U-albumin, Ewprth Sleepiness Scale, Apnoea hypopnoea index, and Oxygen desaturation index are presented as median with interquartile range [25%; 75%]. The remaining data are presented as mean (SD). *From Epworth Sleepiness Scale, self-reported data. Statistics were performed using paired t-test or Wilcoxon signed rank test.
treatment was median 73% [57; 93], total range from 20% to 100%. There was no correlation between changes in BP parameters and adherence or follow-up time (data not shown). When excluding subjects with CPAP adherence below 50% (n = 3), BP changes on all parameters were the same as for the whole group (data not shown).

Univariate correlation analysis showed no association between baseline AHI and changes in BP. Baseline AHI was correlated to changes in ESS ($r = 0.62$, $p = 0.008$), but not to baseline ESS or adherence to CPAP treatment.

### 3.5. Renal and Metabolic Parameters

Changes in metabolic and renal characteristics at follow-up are shown in Table 3; no significant changes were observed in BMI, HbA1c, or cholesterols. Renal function remained unchanged, whereas albuminuria decreased significantly 3 [-1; 31] mg/24h ($p = 0.025$). There was no association between changes in BP and eGFR at baseline or at follow-up, and the reduction in albuminuria was not related to changes in any of the BP parameters, eGFR (at baseline or at follow-up), or mean SaO$_2$ at follow-up (tested by univariate correlation analysis, data not shown).

### 3.6. SF36-Questionnaire on Quality of Life

Patients experienced improved quality of life with regard to vitality, social functioning, emotional role, and mental health, whereas no significant changes in physical functioning, physical role, general health, or bodily pain were seen (Table 4). Baseline eGFR was significantly associated to follow-up SF-36 score ($r = 0.50$, $p = 0.042$), but not baseline SF-36 score ($r = 0.48$, $p = 0.052$). No correlation of SF-36 baseline or follow-up and AHI or Epworth at baseline or follow-up.

#### Table 4. SF36 scores at baseline and follow-up.

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Follow-up</th>
<th>$p$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical Functioning</td>
<td>78 (31)</td>
<td>79 (32)</td>
<td>0.78</td>
</tr>
<tr>
<td>Physical Role</td>
<td>63 (49)</td>
<td>67 (48)</td>
<td>0.42</td>
</tr>
<tr>
<td>General Health</td>
<td>67 (26)</td>
<td>69 (26)</td>
<td>0.55</td>
</tr>
<tr>
<td>Vitality</td>
<td>65 (26)</td>
<td>73 (23)</td>
<td>0.0004</td>
</tr>
<tr>
<td>Bodily Pain</td>
<td>73 (17)</td>
<td>77 (23)</td>
<td>0.37</td>
</tr>
<tr>
<td>Social Functioning</td>
<td>87 (19)</td>
<td>94 (11)</td>
<td>0.008</td>
</tr>
<tr>
<td>Emotional Role</td>
<td>69 (48)</td>
<td>78 (42)</td>
<td>0.02</td>
</tr>
<tr>
<td>Mental Health</td>
<td>86 (20)</td>
<td>91 (15)</td>
<td>0.006</td>
</tr>
</tbody>
</table>

Scores for quality of life using SF36 questionnaire at baseline and at follow-up from all 17 participants. Data are presented as mean (SD). Procedure for scoring the SF36 questionnaire was RAND 36-Item Health Survey 1.0 from International Resource Center for Health Care Assessment (Boston, MA). The scales range from 0 (minimal well-being) to 100 (maximal well-being). Statistics were performed using paired t-test.
3.7. Plasma Levels of Syndecan-1

There was no change in p-syndecan-1 from baseline to follow-up (18 [15; 25] vs. 19 [16; 23] ng/mL, \( p = 0.41 \)).

3.8. Plasma Levels of Vasoactive Hormones

No changes were seen from baseline to follow-up in plasma levels of the vasoactive hormones; P-aldosterone (159 [131; 259] vs. 183 [115; 268] pmol/L, \( p = 0.87 \)), P-angiotensin II (13 [7; 55] vs. 11 [7; 30] pg/mL, \( p = 0.11 \)), plasma renin concentration (26 [8; 67] vs. 16 [10; 48] pg/mL, \( p = 0.83 \)), or AVP (0.4 [0.4; 0.7] vs. 0.5 [0.3; 0.8] pmol/L, \( p = 0.28 \)).

3.9. Urinary Excretion of AQP2 and ENaCγ

From baseline to follow-up, no significant changes were seen in urinary excretion of AQP2 (1.4 [1.1; 1.8] vs. 1.3 [1.1; 2.6] ng/min, \( p = 0.88 \)) or ENaCγ (1.2 [1.0; 1.6] vs. 1.2 [0.9; 1.8] ng/min, \( p = 0.54 \)).

4. Discussion

The main findings of this study were a statistically significant and clinically relevant decrease in 24 h and daytime BP after short term CPAP treatment in patients with impaired renal function (mean eGFR 66 mL/min/1.73 m²) and a reduction in albuminuria. The decrease in nocturnal BP was not statistically significant, and there was no difference in nocturnal BP decrease or frequency of non-dipping. Renal function remained unchanged.

Previous studies reported different results of the BP response to CPAP. Becker et al. found a significant (>10 mmHg decrease) in systolic and diastolic using 24 hours BP measuring, both during day- and nighttime [31], Hermida et al. found a small (<3 mmHg) and statistically non-significant decrease in 24 h BP [32], whereas Durán-Cantolla et al. [33] measured a similar and significant fall in 24 h, day and nighttime BP. In the latter study, the number of non-dippers was reduced after treatment [33]. All studies comprised mainly hypertensive patients diagnosed with OSA, whereas no information was given about the patients’ renal function and eventually diabetes. Hence, differences in baseline characteristics between studies may explain some of the divergent findings of BP response. Moreover, patients in the studies had different baseline levels of BP, AHI, and ESS, which may also influence the response to CPAP.

In the present study, five patients had changed their antihypertensive treatment. However, the difference in mean DDD at baseline and follow-up was less than 3%. We do not believe that such a small change in DDD can solely explain the BP response at follow-up.

Our study, in contrast to the previous studies, included patients with known impaired renal function. Patients were recruited from a renal outpatient clinic, and not primarily based on referral to a sleep clinic, which most likely explains why the patients in the present study had lower AHI and less sleep symptoms.
compared with previous studies. However, in the present population, we demonstrated that it is possible to lower BP in patients with moderate-to-severe OSA using CPAP treatment. A previous meta-analysis of CKD patients demonstrated that a 5 mm Hg reduction in office BP reduced the risk of major cardiovascular events with 17%. Thus, the reduction we demonstrated in this population is of clinical relevance. One prevalence study found that as many as 40% of CKD3-4 patients suffered from moderate-to-severe OSA [1], whereas we in a preceding study only found moderate-to-severe OSA present in 22% of CKD3-4 patients [21]. However, based on our studies, we find it reasonable to suggest that patients with CKD should be examined for presence of OSA and treated, if moderate-to-severe OSA is present.

We also investigated the effects of CPAP treatment on central blood pressure derived from applanation tonometry. To our knowledge, no data have been reported on 24 h ambulatory central BP changes as response to CPAP treatment. Prior to our study, Litvin et al. [34] and Hoyos et al. [35] reported a decrease in central BP measured as spot measurements in an in-office set-up after three and eight weeks CPAP treatment, respectively. Both studies found a similar decrease in mmHg in central and peripheral BP after treatment. In agreement with the previous studies, we found a tendency to a decrease in central BP, however, in our study not statistically significant.

As expected, we found that AHI and ODI decreased, and mean oxygen saturation increased at follow-up in good agreement with a Cochrane review [7]. These findings also documented that patients adhered to the treatment.

In our study we found a decreased level of urinary excretion of albumine at follow-up, and renal function remained unchanged measured by eGFR. We did not demonstrate any correlation between the BP changes and renal function. We did not demonstrate any changes in metabolic parameters (blood cholesterol, HbA1c, or BMI). Previous studies have evaluated the effect of CPAP treatment on renal parameters. In a retrospective cohort study, Puckrin et al. reported slower progression of renal disease and lower levels of proteinuria in CKD3-5 patients with adherence to CPAP than non-adherent counterparts [10], but BP levels were unchanged at follow-up. Thus, presumably, BP is not, or at least not the only, important factor. Other authors have shown an association between nocturnal hypoxia and declining renal function [5] [6]. Hence, elevated oxygen levels associated to CPAP treatment may be of importance in explaining the possible renoprotective effect of CPAP treatment on renal function. However, we did not demonstrate this possible association in our study. However, the finding of reduced albuminuria after CPAP treatment adds to the beneficial profile of this treatment in patients with CKD and OSA. As in previous studies, we did not demonstrate any effect of CPAP treatment on BMI or other related metabolic factors [36] [37]. However, even though patients were obese, follow-up time was relatively short to expect changes in BMI and the other parameters without any lifestyle intervention.
In the present study, we did not demonstrate any significant change in reporting of sleep symptoms (ESS). Self-reported quality of life (SF-36) was reported higher on mental parameters at follow-up. Other studies have demonstrated less pronounced sleep symptoms after CPAP treatment [7] [37] [38]. These studies comprised subjects with both higher and identical levels of sleep symptoms as in our study. However, none of the participants in these studies suffered from CKD. Hence, in our population, sleep symptoms may be more related to renal disease than OSA, blunting the effect of CPAP treatment. The changes in ESS were correlated to AHI. This implies that the effect on sleep symptoms is more well-defined in more severe degrees of OSA.

Although patients in the present study suffered from renal failure and had hypertension and diabetes as frequent comorbidities, we demonstrated improved quality of life with respect to vitality (energy and fatigue) and mental parameters with no changes in physical parameters. Two previous studies have reported similar or more pronounced improvements of quality of life after 4 - 6 weeks CPAP treatment [8] [39]. In one of these studies, participant suffered from more severe OSA, and in both, patients reported more severe sleep symptoms. Interestingly, we observed an improvement of quality of life in a heavier diseased population with less severe OSA and sleep symptoms. However, eGFR was correlated to overall quality of life at follow-up, which suggest that presence of renal disease is an important factor for quality of life in our population. This may be one explanation for the lack of effect on the patient’s physical health parameters in this study.

We did not demonstrate any changes in p-syndecan-1. In vascular diseases, syndecans are shedded from the glycocalyx protection layer in the cardiovascular system [18]. In a previous study, we demonstrated higher plasma levels of syncecan-1 in a hypertensive population with sparse disease burden compared to healthy controls [19]. Other studies have reported higher levels of syndecans associated to declining renal function in a CKD population [40] and to overt heart failure in hypertensive patients [41]. We did not demonstrate any changes in syncecan-1 levels after CPAP treatment. We included only a small population with other cardiovascular risk factors. The over-all cardiovascular risk profile may be a stronger negative influence than an eventual positive influence of CPAP treatment.

We did not demonstrate any effect on renal handling of sodium (ENaCγ and AQP2) or vasoactive hormones in relation to CPAP treatment. One of the explanations for the high occurrence of OSA in CKD patients is sodium and water retention mediated by abnormal renin-angiotensin-aldosterone system (RAAS) activity [42]. In patients with OSA, an abnormal diurnal RAAS activity has been reported [43], and one study has shown, that both OSA severity and BP levels were reduced when adding aldosterone antagonists to the antihypertensive treatment in hypertensive OSA patients [44]. Hence, when analysing the effect of CPAP treatment, it is relevant to evaluate eventual changes in vasoactive hor-
mones and renal handling of sodium and water as an explanation for BP response. The lack of changes in plasma levels of hormones in the present study may be related treatment with antihypertensive agent blocking the RAAS system.

Strength of this study is that we at follow-up, in addition to adherence registrations, completed sleep examination in all patients to confirm the use of CPAP-treatment on improved sleep quality (AHI, ODI, and oxygen saturation).

The response on central BP was evaluated from 24 h measurements, and albuminuria was evaluated from 24 h urine collection instead of spot urine measurement. We included a relatively new plasma marker of cardiovascular stress, syndecan-1.

It is a weakness that time from baseline to follow-up time varied from 72 to 139 day. However, we aimed to evaluate the effect short term treatment and defined that as approximately three to four months of intervention, and we did not expect amplification of findings within the present used timeframe. Another weakness of the study is that a few subjects experienced changes in antihypertensive treatment. However, it was not ethically justified not to treat these patients with usual care, and the change in mean DDD was only minor. We did not include a sham or placebo intervention to eliminate the effect of biases or to address the Hawthorne effect.

5. Conclusion

CPAP seems to be an effective blood pressure lowering treatment in patients with mean eGFR 66 mL/min/1.73 m² and sleep apnoea with beneficial effects on albuminuria. Larger studies are needed to verify this finding and explore potential effects on the progression of renal failure.

Acknowledgements

The authors greatly acknowledge the skillful assistance of our laboratory technicians: Anne Mette Ravn, Kirsten Nygaard, and Henriette Vorup Simonsen.

The authors also greatly acknowledge the skilful assistance from Nurses Marianne Kirkegaard and Anja Mailund Mikkelsen in the Sleep Apnoea Clinic, Department of Medicine, Holstebro Hospital.

The authors thank the Department of Clinical Biochemistry, Holstebro Hospital for help in routine analyses.

Conflicts of Interest

The authors have no conflicts of interest.

Funding

This research project has received research funding from The Central Denmark Region’s Research Foundation for Health Science, the Danish Heart Association, and the Axel Muusfeldt Foundation.
References


[23] Berry, R.B., Budhiraja, R., Gottlieb, D.J., Gozal, D., Iber, C., Kapur, V.K., Marcus, C.L., Mehra, R., Parthasarathy, S., Quan, S.F., Redline, S., Strohl, K.P., Davidson

**DOI:** 10.4236/ojneph.2019.91001


